These reports are interesting because they focus on new potential strategies of TRK inhibitors’ administration in terms of clinical setting (adjuvant vs. metastatic disease) and combinations (single agent vs. combined treatment). The gene discussed is NTRK1; the disease is metastatic neoplasm.